We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
All good if the money is in. There can still be clauses that involve the company to do or show something that takes time. I recall we were informed that Faron will get a grant and the paperwork still needs to be done. They said they will not particularly communicate once the agreement is signed. Just hoping the prevailing conditions are still favorable for HIBISCUS.
I think Faron had stated that it had received the funds from the DoD .
Perhaps the delay is just getting allocation of patients in these hospitals .
I expect so many trials have been initiated in the last year , they are fighting over patients , particularly when it is Harvard University etc - the most highly sought after medical school.
In an article that was released during May Jalkanen said there will be RNS when they'll get permission to begin Hibiscus at the states. So it might have something to do with FDA I guess. Hope we'll have news shortly.
We don’t actually know HIBISCUS hasn’t started. Just because the first patient dosing has not been RNS’d does not mean it hasn’t happened.
Just wondering what delays the HIBISCUS start. Don’t want to speculate with too any reasons but there can be too many options for patients or doctors to choose? But if it has it’s niche it should get started! It is said to start once a permission given. Is it still pending because of FDA? or DoD? or Faron? If the company were under an evaluation for an M&A, I think DoD grant would be in hold and delaying the start? Pure speculation!
If Bex shows further promise with more data Faron will be snapped up in a blink
If I have correct understanding, 13% of those are in pipeline of some modern cancer treatment and rest 87% are those refractory ones out of other options anymore but Bex tries to.
Roughly 1.3b people living in EU and US out of them 16% is 65+ year old. Median age getting cancer is 66 and more than 1% of 60+ year and older people get it annually. So we have 1.3b x 16% x 1% = 2 080 000 new cancer cases at the age group 60+ annually. General cancer statistics say 66% are alive after 5 years and the rest 34% are not, meaning 707 200 patients die sooner. If that is the market that Faron will try to solve, market size is 35b-70b (With a mid price 75 000 the market size is 53b). Pretty close to Faron’s estimate 56b$ for IO market in their target countries in total in 2025.
Or spin it the other way...competing majors will not want to be out of the race and pay over the odds for Bex.
I am 100% certain there is room in the market for more than one cancer drug.
The worry is that GSK get to market first with the powerful PR team and salespeople, we might be out of the race.
So that's roughly £1.5bn deal for a drug that sounds like a similar stage where Bex is at - have a I read that correctly?
c7 x our current MC equates to c£28 sp. I would assume that further proving up will equate to a higher MC, should someone wish to take us out!
I had not seen that story Iceman, it does show there are deals to be had out there. The further we get on our own though the bigger the potential deal when we do actual make one...
Link for anyone else who had missed it - https://www.ft.com/content/a8edb8fb-4ab6-49ed-8c81-326c862d75ec
What’s everyone’s thoughts on the GSK tie up with biotech cancer specialists ?
The granting of the patent is seen as ' key' by Faron .
Key , as in it will play a major part in unlocking value for the therapy .
20 years is standard patent life , so I expect this was filed in 2017 .
Potential for extensions .
100% wholly owned , with options to go many ways .
I think we are definitely entering the SSV time frame now .
405 :)